Clinuvel Pharmaceuticals (ASX:CUV) Interest Expense: A$-5.04 Mil (TTM As of Dec. 2025)

What is Clinuvel Pharmaceuticals Interest Expense?

Clinuvel Pharmaceuticals ASX:CUV -0.39% 86 Interest Expense is A$-5.04 Mil as of Dec. 2025. GuruFocus rates ASX:CUV with a GF Score™ of 86/100 and a GF Value™ of A$17.74 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Clinuvel Pharmaceuticals's interest expense for the six months ended in Dec. 2025 was A$ -2.55 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Clinuvel Pharmaceuticals's Operating Income for the six months ended in Dec. 2025 was A$ 13.51 Mil. Clinuvel Pharmaceuticals's Interest Expense for the six months ended in Dec. 2025 was A$ -2.55 Mil. Clinuvel Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 was 5.29. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Clinuvel Pharmaceuticals (ASX:CUV) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Clinuvel Pharmaceuticals's Interest Expense for the six months ended in Dec. 2025 was A$-2.55 Mil. Its Operating Income for the six months ended in Dec. 2025 was A$13.51 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was A$0.02 Mil.

Clinuvel Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2025 )	/	Interest Expense (Q: Dec. 2025 )
	=	-1	*	13.511	/	-2.554
	=	5.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Clinuvel Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's Interest Expense can be seen below:

Clinuvel Pharmaceuticals Interest Expense Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Interest Expense

Get a 7-Day Free Trial

-1.62

-2.27

-3.19

-4.45

-4.46

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Interest Expense	Get a 7-Day Free Trial															-2.02	-2.43	-1.98	-2.49	-2.55

86GF Score

Clinuvel Pharmaceuticals Ltd ASX:CUV

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Clinuvel Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-5.04 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of A$-5.04 Mil mean?

Clinuvel Pharmaceuticals (ASX:CUV) has a Interest Expense of A$-5.04 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Clinuvel Pharmaceuticals and its competitors.

Is Clinuvel Pharmaceuticals' Interest Expense too high?

Clinuvel Pharmaceuticals' current Interest Expense is A$-5.04 Mil. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Clinuvel Pharmaceuticals' Interest Expense compare to VRTX and REGN?

Clinuvel Pharmaceuticals' Interest Expense of A$-5.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Interest Expense is A$-5.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Clinuvel Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.74, compared to a current price of A$10.21 — trading 42.4% below its estimated fair value. The current Interest Expense is A$-5.04 Mil. Clinuvel Pharmaceuticals' overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Interest Expense is A$-5.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of A$10.21 is trading 42.4% below its estimated GF Value™ of A$17.74. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ASX:CUV:

Interest Expense: A$-5.04 Mil
GF Value™: A$17.74 vs. price of A$10.21 (42.4% below fair value)
GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:RAC ASX:CU6 ASX:TTX ASX:SPL ASX:OCC ASX:ATH ASX:ACW ASX:RCE ASX:DXB ASX:ILA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CLVLY:USA CLVLF:USA UR9:Germany

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000

Website https://www.clinuvel.com

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

86GF Score

Get the complete analysis for ASX:CUV

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$10.21

Price

A$17.74

GF Value

View ASX:CUV Analysis

See Interest Expense data for all stocks →